Please sign in to view your cart.
Don't have an account? Create one for free.
Methods: Data Sources: Articles published from January 1, 2010, to January 30, 2024, were selected from the PubMed, Cochran, and Embase databases in the English language. Data Extraction and Synthesis: The review was guided by Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines. Two independent reviewers screened 7536 records in databases 7017 Records Excluded (articles without pharmacological treatment). After quality appraisal, only 15 articles were assessed for eligibility. Data related to study design, interventions, controls, outcome measures, and relevant findings were extracted, and then narrative analysis was performed.
Results: Study Selection: Clinical trials recruited individuals who were post-chemotherapy, experienced CIPN symptoms, and received medications for treatment. Of 15 studies, only 10 were included (2 records did not address the research question, 1 duplicate). And two records addressed prevention, not treatment. In studies, duloxetine showed exceptional tolerance. However, a recent clinical study, conducted showed that duloxetine had a low tolerance. 20% of the patients discontinued the medicine due to its lack of efficacy, while 37% discontinued it due to experiencing side effects.
Discussion: Conclusion From this scoping review., it is advised to integrate many therapeutic approaches and modify the dosage to prevent negative occurrences. Using combinations may be beneficial for conditions that are unresponsive to treatment or opioid-dependent and who have difficulty tolerating high doses of duloxetine
Other: Limitations: In this scoping review, there are significant limitations, such as inconsistent outcome measurements and the absence of standardized treatment methods, as well as various forms of cancer
This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.